Five new drugs have been applied for clinical application. This pharmaceutical company has been put into operation

[pharmaceutical network industry trends] in recent years, the whole Chinese medical and health industry is moving towards a very healthy and sustainable development direction In this context, the field of innovative drugs in China has also been developing rapidly A group of innovative drug companies are successively taking out innovative drugs made in China from their product pipelines, pushing China to become a powerful country of innovative drugs It is understood that from 2014 to 2018, CDE (drug evaluation center of the State Drug Administration) approved a total of 28 innovative drugs, an increase of 125% in five years In the near future, China's innovative drug market has made a big breakthrough again
Data shows that in recent two weeks (12.13-12.27), 49 acceptance numbers (34 varieties) of new drug / imported clinical applications have been undertaken, of which 32 acceptance numbers (22 varieties) are domestic new drug clinical applications, 17 acceptance numbers (12 varieties) are imported new drug clinical applications; from the perspective of drug type, 30 acceptance numbers (18 varieties) are chemical drugs, 18 acceptance numbers (15 varieties) are biological products for treatment, 1 Acceptance number (1 variety) is Chinese patent medicine It can be seen from the fact that the number of domestic new drugs applied for clinical application is nearly double that of imported new drugs that domestic enterprises are transforming to innovative development, and more and more domestic new drugs will be applied for listing in the future In addition, it is worth noting that in recent two weeks, there are 7 acceptance numbers (5 varieties) of clinical applications of Hengrui medicine that have been accepted by CDE: shr2150 is a toll like receptor 7 (TLR-7) inhibitor developed by Hengrui medicine, which is intended to be used in the treatment of advanced malignant tumors Its capsule has been approved for clinical application in November 2018, and phase I clinical trial will be carried out in the near future, and the clinical application is injection Fluzopali capsule has been declared on the market in October 2019, and is expected to become the first approved domestic PARP inhibitor, which may be a new clinical indication It is reported that fluzopali is a kind of poly adenosine diphosphate ribose polymerase inhibitor, which can specifically kill BRCA mutated tumor cells, and is used to treat recurrent ovarian cancer with BRCA1 / 2 pathogenic or suspected pathogenic mutation that has undergone second-line or more chemotherapy Up to now, Hengrui pharmaceutical has invested about 190 million yuan in the R & D project Apatinib mesylate tablets have been approved for marketing in October 2014 In 2018, the terminal sales of apatinib mesylate tablets in public medical institutions in China exceeded 2 billion yuan This is a clinical application for new indications It is a small molecule tyrosine kinase inhibitor independently developed by Hengrui pharmaceutical It can selectively inhibit the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR-2), thus inhibiting tumor angiogenesis and tumor growth Up to now, the R & D cost of relevant projects has been about 28146 million yuan Abitrone acetate tablet (I) is an improved new drug It was developed by Janssen cilag international N.V company earlier, and its trade name is zytiga It was approved to be listed in the United States in April 2011, and now it has been listed in Canada, the European Union, Japan and other countries In 2015, the drug was approved in China under the trade name of Zeke It is reported that the abitrone acetate tablet developed by Shengdi pharmaceutical, a subsidiary of Hengrui pharmaceutical, can be transformed into abitrone in vivo Up to now, it has invested about 39.05 million yuan in the research and development of the project